Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Treasury Shares (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Treasury Shares readings, the most recent being $712000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares fell 82.02% year-over-year to $712000.0, compared with a TTM value of $712000.0 through Dec 2025, down 82.02%, and an annual FY2025 reading of $712000.0, down 82.02% over the prior year.
  • Treasury Shares hit $712000.0 in Q4 2025 for Apellis Pharmaceuticals, down from $4.0 million in the prior quarter.
  • The five-year high for Treasury Shares was $4.3 million in Q4 2023, with the low at $712000.0 in Q4 2025.
  • Median Treasury Shares over the past 5 years was $3.6 million (2022), compared with a mean of $2.8 million.
  • The sharpest move saw Treasury Shares skyrocketed 191.59% in 2022, then tumbled 82.02% in 2025.
  • Year by year, Treasury Shares stood at $1.2 million in 2021, then soared by 191.59% to $3.6 million in 2022, then rose by 20.41% to $4.3 million in 2023, then dropped by 7.91% to $4.0 million in 2024, then plummeted by 82.02% to $712000.0 in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $712000.0, $4.0 million, and $4.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.